Status:

COMPLETED

The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma

Lead Sponsor:

Mayo Clinic

Conditions:

Glioma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. Investigators then plan to compare patterns of failure with target volumes, ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Age \> or equal to 18 years
  • ECOG PS \< or equal to 3
  • Histologically confirmed or radiographic evidence of recurrent/progressive glioma.
  • History of radiation therapy to the brain for prior diagnosis of glioma
  • Planned radiation treatments at Mayo Clinic Rochester
  • Provide informed written consent
  • Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study, IRB number 15-000136 (blood draw optional)
  • Willing to return to enrolling institution for follow-up during Active Monitoring Phase of the study.
  • Exclusion Criteria
  • More than one prior course of radiotherapy or prior prescription doses exceeding 60 Gy to re-irradiation target volumes
  • Unable to undergo MRI scans with contrast
  • Unable to undergo an 18F-DOPA-PET scan (e.g., Parkinson's Disease, taking anti dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists.)
  • Note: Other potentially interfering drugs: amoxapine, amphetamine, benztropine, buproprion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, paroxetine, citalopram, and sertraline). If a patient is on any of these drugs, list which ones on the On-Study form.
  • Any of the following:
  • Pregnant women
  • Nursing women
  • Men or women of childbearing potential who are unwilling to employ adequate contraception

Exclusion

    Key Trial Info

    Start Date :

    September 29 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 16 2021

    Estimated Enrollment :

    21 Patients enrolled

    Trial Details

    Trial ID

    NCT03242824

    Start Date

    September 29 2017

    End Date

    June 16 2021

    Last Update

    March 14 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Mayo Clinic in Rochester

    Rochester, Minnesota, United States, 55905